Although these patients showed significantly higher levels of D-2HG compared to leukemia or glioma patients harboring IDH1/2 mutations, they do not have a predisposition to developing gliomas, leukemia or other malignancies [55]. This evidence concerns the gene IDH1 and central nervous system cancer.